Abstract: A balloon catheter is provided with a main tube and an air tube therein. The main tube is provided with a central lumen to allow the balloon catheter to travel across and be guided along a guidewire during insertion into a vasculature of a patient. The air tube is configured to transfer fluid, such as air, to a balloon for inflating and deflating the balloon. The air tube can be embedded within the inner and outer surfaces of the main tube. Holes are cut into the main tube and a portion of the air tube to expose the air tube to the environment outside of the main tube. The holes allow for fluid communication between the air tube and the balloon. The holes are cut or sheared at a direction that is lateral to the longitudinal direction of the catheter tube.

Abstract: Methods of treating a dengue virus (DENV) infection in a human subject, comprising administering to the human subject a compound of Formula (I), or pharmaceutical composition comprising a compound of Formula (I): A compound of Formula (I) can be administered within onset of fever to 72 hours of fever onset due to dengue infection and then every 6 to 12 hours until there is an improvement in the infection or between from about 1 day to about 10 days. The methods of the invention can be used to treat primary and secondary DENV1-4 viral infections.

Abstract: Methods of treating a dengue virus (DENV) infection in a human subject, comprising administering to the human subject a compound of Formula (I), or pharmaceutical composition comprising a compound of Formula (I): A compound of Formula (I) can be administered within onset of fever to 72 hours of fever onset due to dengue infection and then every 6 to 12 hours until there is an improvement in the infection or between from about 1 day to about 10 days. The methods of the invention can be used to treat primary and secondary DENV1-4 viral infections.

Abstract: Methods of treating a dengue virus (DENV) infection in a human subject, comprising administering to the human subject a compound of Formula (I), or pharmaceutical composition comprising a compound of Formula (I): A compound of Formula (I) can be administered within onset of fever to 72 hours of fever onset due to dengue infection and then every 6 to 12 hours until there is an improvement in the infection or between from about 1 day to about 10 days. The methods of the invention can be used to treat primary and secondary DENV 1-4 viral infections.

Abstract: Methods of treating a dengue virus (DENV) infection in a human subject, comprising administering to the human subject a compound of Formula (I), or pharmaceutical composition comprising a compound of Formula (I):A compound of Formula (I) can be administered within onset of fever to 72 hours of fever onset due to dengue infection and then every 6 to 12 hours until there is an improvement in the infection or between from about 1 day to about 10 days. The methods of the invention can be used to treat primary and secondary DENV-4 viral infections.

Abstract: Methods of treating a dengue virus (DENV) infection in a human subject, comprising administering to the human subject a compound of Formula (I), or pharmaceutical composition comprising a compound of Formula (I): A compound of Formula (I) can be administered within onset of fever to 72 hours of fever onset due to dengue infection and then every 6 to 12 hours until there is an improvement in the infection or between from about 1 day to about 10 days. The methods of the invention can be used to treat primary and secondary DENV1-4 viral infections.

Abstract: Methods of treating a dengue virus (DENV) infection in a human subject, comprising administering to the human subject a compound of Formula (I), or pharmaceutical composition comprising a compound of Formula (I): A compound of Formula (I) can be administered within onset of fever to 72 hours of fever onset due to dengue infection and then every 6 to 12 hours until there is an improvement in the infection or between from about 1 day to about 10 days. The methods of the invention can be used to treat primary and secondary DENV1-4 viral infections.

Abstract: The present invention relates to a tricyclic heterocyclic derivative according to Formula (I), wherein the variables are defined as in the specification, or to a pharmaceutically acceptable salt or solvate thereof. The present invention also relates to pharmaceutical compositions comprising said tricyclic heterocyclic derivatives and to their use in therapy, for instance in the treatment or prevention of serotonin mediated disorders, such as obesity.

Abstract: The present invention relates to a tricyclic heterocyclic derivative according to Formula (I), wherein the variables are defined as in the specification, or to a pharmaceutically acceptable salt or solvate thereof. The present invention also relates to pharmaceutical compositions comprising said tricyclic heterocyclic derivatives and to their use in therapy, for instance in the treatment or prevention of serotonin mediated disorders, such as obesity.

Abstract: An apparatus and system for alleviating the symptoms of scotopic sensitivity syndrome for a user wearing eyeglasses is provided. The eyewear comprises one or more layers, a first band, and a second band. Each of the layers comprises a coloured film. The first and second bands are attached to the one or more layers. When the eyewear is in use, the one or more layers are placed in front of the eyeglasses and the first band is attached to the second band at a location behind the user's head. Systems for assisting in viewing a computer screen or printed matter are also provided.

Abstract: A computerized system for simultaneous operation of multiple environments and method for storing distinct data types separately is disclosed. The computerized system includes a plurality of main host, sub-host, data storage and network devices wherein data of a first type is stored on main host, data storage and network devices and data of a second type is stored on one of the sub-host, data storage and network devices, wherein data of a third type is stored on at least another one of the sub-host, data storage and network devices, and data of a forth type is stored on at least another one of the sub-host, data storage and network devices, wherein all of the data types requires controlling access thereto. The invention provides for ensuring the integrity and separation of the data stored on the sub-host, data storage and network devices. It also prevents misappropriation of data stored on the devices.

Abstract: Method, apparatus and computer program product are provided to increase the efficiency of copy operations in a data storage system. Multiple virtual storage controllers are each in communication with a host device and to two virtual storage servers. Both virtual storage servers are attached to a respective automated storage library. Each controller includes a copy queue. After directing that a volume of customer data be stored through one of the servers on media in the associated library, an initiating controller queues in a copy queue a request to copy the volume to the other library. If the request is not processed by the initiating controller within a very short period, the initiating controller broadcasts the copy request to the other controllers. Preferably, the copy request is transmitted first from the initiating controller to a routing device in one of the servers which broadcasts the request to each other controller. The copy request is queued in a copy queue of each other controller.

Abstract: A method is provided for freeze-drying multiple samples of viable microorganisms which method comprises: (i) providing a container comprising multiple wells; (ii) dispensing multiple liquid samples, each sample comprising a viable microorganism, into separate wells of the container; (iii) placing the container in a freeze-drying apparatus; and (iv) freeze-drying the samples present in the wells under conditions that substantially maintain the viability of the microorganisms. Also provided is a container comprising multiple wells, each well comprising a viable freeze-dried sample of a microorganism.

Abstract: A method of use and apparatus for estimating repair cost, particularly applicable to cost estimation of interspaced defect damaged vehicle surfaces. The method of use of the present invention provides that a defect count be made for a predetermined representative area; that a determination of relative severity be made with respect to at least one defect within the representative area; and that the repair estimate is then based upon the defect count information and defect severity. A set of physical templates may be provided, with a first template allowing the calculation of the number of dents per surface area, and a second template for grading, comparing, or otherwise determining the size or severity of the individual dents. Additionally, the defect count data and defect severity data may be determined with an electronic scanning means. Various formulae may be employed (manually or electronically) for calculating the cost estimate to repair the damaged surface.